News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Dinar News, Articles and Videos with Contenting
The Dinar is a currency that has been used in Iraq since 1932. It is currently the official currency of Iraq, and is used in many other countries in the Middle East. While it is a relatively stable currency, in recent years the value of the Dinar has fluctuated due to the instability in the region. This has led to speculation about the future of the currency, as well as a number of articles and videos discussing the currency. This section contains a collection of news, articles and videos about the Iraqi Dinar.
CROSSJECT reports financial results for 2024 - ForexTV
Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer USA.Visibility gained on pipeline programs developed in collaboration with Eton Pharmaceuticals, Inc (Eton).Cash position increasing significantly to 7 million euros as of December 31, 2024. Dijon, France, March 27, 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ) a specialty pharmaceutical company in late-stage development and registration of ZEPIZURE®, its emergency solution for the management of epileptic seizures, announces progress in its clinical and regulatory development activities and commercial strategy in the United States, and publishes its financial results for the year ending December 31, 2024. Patrick ALEXANDRE, Chairman of the Executive Board of CROSSJECT, announces: We continue to make progress towards the major inflection points that will transform CROSSJECT in 2025 and are likely to generate substantial shareholder value in the years to come. The execution of our contract with the Department of Health and Human Services; Administration for Strategic Preparedness and Response / BARDA for $92 million, which could rise to $155 million if all its options are exercised, has continued as planned and is accelerating in line with the increase in expenses linked to the development of ZEPIZURE®. In 2024, we recorded research and development costs re-invoicing of 8.2 million euros, compared with 6.2 million euros in 2023. This contract with BARDA, registered under number 75A50122C00031, includes up to $32 million to advance the development of ZEPIZURE® through to Food and Drug Administration (FDA) approval for the management of status epilepticus in adults and children over 2 years of age in the United States. It also provides for the supply to the US Government of $60 million worth of ZEPIZURE®, following FDA approval under the Emergency Use Authorization (EUA) procedure. This milestone is the focus of our activities today. Our recent exchanges with the FDA have clarified the requirements for our ZEPIZURE® product in the treatment of epileptic seizures resulting from poisoning by a neurotoxicant or insecticide under this emergency procedure (EUA), and we estimate that a response from the FDA might be obtained in 2025. In terms of industrial production, we have achieved major successes in 2024 and in 2025, and we continue to work with our Contract Development Manufacturing Organisation (CDMO) to finalize the dossier that BARDA will submit to the FDA. Our supply-chain organization, which today includes Eurofins Scientific as an injectables specialty manufacturer, has confirmed its performance and achieved stability for its regulatory ZEPIZURE® batch produced in July 2024. The manufacture of additional validation batches, including aseptic filling operations at Eurofins Scientific, is currently underway and is proceeding successfully. These core production steps support the previously announced timetable for BARDA's submission to the FDA under the EUA procedure. At the same time, CROSSJECT expects to file a New Drug Application (NDA) with the FDA in the by mid-2026 for the commercialization of ZEPIZURE® in the United States for the treatment of status epilepticus. We are focused on the final stages of development, with the preparation of a bioequivalence study that will form an integral part of the New Drug Application (NDA). This study will mimic our previous bioequivalence study, published on November 02, 2022, yet using a US-registered reference product as comparator, and will be at the same dose of 10mg. It will also include an arm with a 5mg dose to enable ZEPIZURE®, from launch, to compare directly with the intranasal competition, while progressing towards subsequent pediatric approval. As previously stated, CROSSJECT intends to retain the commercial rights to ZEPIZURE® in the United States. In this context, we have strengthened our US team with Tony Tipton, US Chief Operating Officer, a specialty pharmaceutical professional with the experience, including with BARDA, and leadership necessary for the success of ZEPIZURE®. The funds obtained from BARDA from their commercial orders, subject to EUA, will timely help finance ZEPIZURE®'s development towards its NDA in status epilepticus, beyond its EUA, and in broader epilepsy indications. BARDA's commercial orders will also support the commercial roll-out of ZEPIZURE®. Based on historical data, we believe that the ZENEO® platform will continue to demonstrate its ability to reproduce the intramuscular injections of traditional injectables with a high level of precision and low variability. These characteristics of ZENEO, now firmly established, will be essential not only to limit the risks associated with development and the regulatory environment, but also to promote market acceptance in the face of traditional injectable products and other delivery methods, particularly intranasal. The latter products have more variable transmucosal pharmacokinetics, which adds to the practical difficulties of precise administration during seizures. Beyond ZEPIZURE®, our next two main R&D programs, ZENEO® Hydrocortisone and ZENEO® Adrenaline, are also progressing towards filing for registration from H2 2026 onward in the US or Europe. In July 2024, we were awarded a €6.9 million BPI grant as part of the France 2030 plan, which will contribute to the development of ZENEO® Adrenaline. Furthermore, in March 2025, we announced progress in the development of ZENEO® Hydrocortisone by our US partner Eton Pharmaceuticals, Inc (Eton). CROSSJECT has strengthened its collaboration with Eton by making its innovative hydrocortisone formulation (the “CROSSJECT formulation”) available to address the hospital market for adrenal insufficiency. CROSSJECT will receive a royalty of around 10% on Eton's net sales. Eton has confirmed its commitment to finalizing the development and manufacturing stages of its adrenal insufficiency product range, including such CROSSJECT formulation, referred to as ET-800, and the unique ZENEO® Hydrocortisone crisis management product, with the aim of capturing a significant share of a total market opportunity of over $200 million in the United States alone. FDA filings are expected from H2 2026 onward. All these positive elements have been opportunities to strengthen our balance-sheet, which we recently consolidated with a financing with Heights Capital Management (HCM) of 12 million euros in February 2024, with a first tranche of 7 millions euros raised at closing, and amended on the occasion of our private placement in December 2024 of over 7 million euros, in which HCM and Gemmes Venture participated, as described below. These transactions with renowned institutional investors, including US investors, were complemented by a capital increase of 8 million euros in June 2024, which was fully covered by the subscriptions of our existing investors. In coordination with the progress of ZEPIZURE® towards its market authorizations and the progress of our other two R&D programs, we continue to actively explore the best ways of financing our rapidly expanding global activities. Philippe Monnot, one of the Founders and Chairman and CEO of Gemmes Venture, our reference shareholder, has confirmed his support, in addition to Gemmes Venture's unwavering participation in the June and December 2024 financings: “The Company's clinical data and recent developments in CROSSJECT's supply chain and constructive exchanges with the FDA have continued to reinforce our confidence in the imminence of the introduction of a major treatment for epileptic seizures, a poorly controlled disease that continues to generate significant clinical needs. What's more, CROSSJECT has delivered several successes with other product candidates in its pipeline, which are exciting preludes to future developments and market launches of other revolutionary injectable products. We reiterate our support for the company and its management.” Thank you, dear shareholders, for your loyal attention, and for your continued support of our efforts. Together, we can improve patients' lives and create value for CROSSJECT. Key financial information at December 31, 2024 (unaudited) In 2024, we continued to finance the development of ZEPIZURE® and other pipeline products, as well as our infrastructure, from several sources: BARDA invoicing: 8.2 million euros were invoiced as reimbursement of R&D costs incurred in 2024, compared with 6.2 million euros in 2023.Research tax credit: 2.8 million recognized in 2024, stable compared with 2023. In February 2024, the company issued a convertible and/or redeemable bond in two tranches to Heights Capital Management (HCM), an institutional investor specializing in growth companies, for a maximum amount of 12 million euros at that date. The first tranche of 7 million euros was received at closing, or 6.3 million euros net. The second tranche of this bond was cancelled and replaced by a new agreement in December 2024 concomitant with the private placement, described below, in which Heights participated, and an issue of a reduced tranche of Convertible Bonds of 2.5 million euros in February 2025 following our Extraordinary General Meeting on January 31, 2025.In June 2024, the company raised around 7.6 million euros net through a capital increase without pre-emptive rights to support the development of ZEPIZURE®.In July 2024, the French government awarded CROSSJECT 6.9 million euros as part of a call for projects under the France 2030 plan, aimed at supporting companies with high growth and innovation potential. An advance payment of 1.7 million euros was made in 2024, with the remainder expected in 2025 and 2026.In August 2024, CROSSJECT also finalized the work related to the “Stimulus Plan” grant and collected the balance of 0.6 million euros in September.In December 2024, the company carried out a private placement with mainly US institutional investors, joined by HCM and Gemmes Venture, accompanied by a warrant issue for a total net amount of 6.6 million euros. In parallel with the transaction, the Company has agreed with HCM to amend the terms and conditions of the existing convertible bonds in February 2024. The amendments, as detailed below, mainly provide for (i) the issue of a second tranche of around 2.5 million euros, which would no longer be subject to the FDA's Emergency Use Authorization for ZEPIZURE® and (ii) an extension of the maturity date of the convertible bonds to December 28, 2027. The table below summarizes our income statement for the years ended December 31, 2024 and 2023: € thousands, as of 31 December 2024 2023 Operating income 13 256 13 326 Operating expenses -26 219 -25 125 Purchase of raw material and supplies -1 624 -1 595 Other purchases and external expenses -10 439 -8 869 Personal expenses -7 797 -7 714 Taxes and duties -280 -267 Depreciation, amortisation and provision -5 671 -6 186 Other expenses -408 -494 Operating profit/loss -12 962 -11 800 Financial income/expense -1 429 -497 Exceptional income/expense -1 230 791 Corporate tax 2 826 2 867 Net profit/loss -12 795 -8 639 *2024 accounts unaudited. In 2024, we continued to strengthen our research and development activities as well as our general operations. As a result, we recorded operating income of 13.3 million euros, stable compared to 2024 but including a marked increase of 2 million euros in BARDA income. Operating expenses increased by 4% in 2024 compared to 2023. In addition, other purchases and external expenses amounted to €10.4 million, compared with €8.9 million in 2023, while the company has maintained the pace of its production work and third-party purchases as part of ZEPIZURE® regulatory development and activities related to other key programs in our pipeline. We have also incurred additional expenses in connection with fees related to financing transactions. As of December 31, 2024, CROSSJECT had 106 employees in France and 2 in the US, a decrease of 5% compared to 2023. Personnel expenses amounted to 7.8 million euros in 2024, compared with 7.7 million euros in 2023, an increase of 1%. We recorded an operating loss of 13.0 million euros, compared to 11.8 million euros in 2023. We recorded a net financial result of -1.4 million euros in 2024, compared to -0.5 million euros in 2023. The increase is mainly due to interest expenses on the HCM convertible bond for an amount of €0.6 million. and to a depreciation of the securities under self-control and liquidity contracts of €0.4M. After taking into account the exceptional result of -1.2 million euros and a tax credit of 2.8 million euros, net profit for 2024 is -12.8 million euros compared to -8.6 million euros in 2023. Cash position At 31 December 2024, CROSSJECT had cash of approximately €7 million compared to €2 million in 2023. Since the beginning of 2025, we have continued to make financing our priority. Based on its financial resources as at March 31, 2025 and historical relationships with its lenders and creditors [as well as with its investors, the company is confident in its ability to finance its business plan until the date when BARDA’s first commercial orders will start. As the outlook for ZEPIZURE® improves and as CROSSJECT devotes resources to research and development of its other candidate products, ZENEO® Hydrocortisone and ZENEO® Adrenaline, the company will continue to actively explore the best ways to finance its activities through equity, debt, public funding and other types of financing throughout 2025. Important steps in 2024 Non-dilutive funding related to ZENEO® Adrenaline In July 2024, the French Government granted 6.9 million euros to CROSSJECT as part of projects under the France 2030 plan, aimed at supporting companies with high growth and innovation potential. An advance of €1.7 million was paid in 2024. Funding with Heights Capital Management In February 2024, the company issued a convertible and/or repayable bond in two tranches to Heights Capital Management (HCM), an institutional investor specialized in growing companies, for a maximum amount of 12 million euros in two tranches, on that date. CROSSJECT then raised the first tranche of 7 million euros and received 6.3 million euros net. The second tranche of this bond was cancelled and replaced by a new agreement in December 2024, concurrent with the private placement, in which Heights participated and an issue of a reduced tranche of 2,5 million euros in February 2025 following our Extraordinary General Meeting of 31 January 2025, as described below. Other dilutive financing In June 2024, CROSSJECT announces the success of its capital increase with maintenance of the preferential subscription right for a gross amount of approximately 8 million euros, as announced on April 30, 2024, and a net amount of approximately 7.6 million euros. This funding is an important step in the further development and recording of ZEPIZURE® and the establishment of operations in the United States in anticipation of its direct marketing. The subscriptions of CROSSJECT’s shareholders, including Gemmes Venture, allowed for a full coverage of the transaction. In December 2024, as part of its private placement of 7 million euros, or 6.6 million euros net, the Company also amended its agreement with HCM to accelerate the provision of financing, amendments that were approved by the Extraordinary General Assembly of 31 January 2025. According to these amendments, the Company agreed with Heights Capital Management (“HCM”) on a modification of the terms and conditions of the existing convertible bonds issued for the benefit of an entity advised by Heights (the “Investor”) in February 2024. These amendments, as detailed below, included the issuance of a second tranche of approximately €2.5 million, which would no longer be subject to FDA Emergency Use Authorization for ZEPIZURE® and an extension of the maturity of convertible bonds until December 28, 2027. Progress in the production of ZEPIZURE® regulatory batches with Eurofins Scientific In July 2024, CROSSJECT achieved several key milestones in the production and batch stability of ZEPIZURE® products. Indeed, CROSSJECT announced the successful completion of a new regulatory batch of ZEPIZURE® in the qualified facilities of Eurofins Scientific. CROSSJECT also announced a new important milestone that complements the successful results achieved with previous batches in stability studies, continuing the positive manufacturing data generated since 2021. Then, in March 2025, CROSSJECT announced the 6-month ambient temperature stability of its regulatory batch which is adding to 9-month data generated on a previous batch produced by Eurofins Scientific in December 2023. Historically, CROSSJECT also reported several positive audits of production sites, conducted in anticipation of possible inspections that the Food and Drug Administration (FDA) could conduct as part of the emergency procedure (EUA). These successes are part of the continuity of the positive audits of the Dijon and Gray CROSSJECT production sites in 2024, which expanded their scope of certification by the National Agency for Drug and Health Product Safety (ANSM) and crystallized the previous positive findings of the BARDA audit. Production batches are a key part of the FDA’s EUA submission for marketing authorization for ZEPIZURE®. This data will also be part of the US market (NDA) marketing authorization application for ZEPIZURE®. Recruitment of Tony Tipton as US Chief Operating Officer CROSSJECT announced on August 19, 2024 the appointment of Tony Tipton, an experienced executive in the field of pharmaceutical specialties, as Director of Operations for the U.S. With more than 25 years of experience in the field of marketing, he brings his expertise in corporate governance and development, market access, commercial service management, marketing and business operations. He joined CROSSJECT after serving as Director of Operations and Commercial Affairs at Xequel Bio, where he was responsible for marketing strategy and pre-sales commercial activities for assets funded by BARDA and the American Institutes of Health (NIH) as well as acquired commercial assets. The appointment of Mr. Tipton will strengthen CROSSJECT’s pre-commercial activities in the US during the preparation of ZEPIZURE® market authorization application. CROSSJECT’s gender equality index reached 93/100 in 2024 For the third year in a row, CROSSJECT’s Gender Equality Index is above 90%. The Gender Equality Index is a tool to measure progress on gender equality across the EU. It is rated on a scale of 1 to 100, where 100 means total equality. Post-period events In addition to the positive events related to the production of ZEPIZURE® following the successes of 2024, and the milestones related to the financing announced in December 2024 described above, CROSSJECT delivered other positive news in the first quarter of 2025: Progress in collaboration with license partner Eton Pharmaceuticals, Inc. and initial market opportunity estimates As part of the development of ZENEO® Hydrocortisone, CROSSJECT has developed a unique ready-to-use liquid formulation of hydrocortisone. This formulation represents a significant innovation in the US market where formulations such as Pfizer’s Solu-Cortef® are effective solutions but require more than 10 steps for reconstitution and blending. As part of joint efforts to provide new solutions for patients with adrenal insufficiency, Eton will develop and market this CROSSJECT formulation as a superior alternative to current injectable products. CROSSJECT will collect a royalty of close to 10% on net sales by Eton of this product, called ET-800 in the Eton pipeline, and retain the right to market the product outside the United States and Canada. Eton hopes to capture a significant share of this hospital market of approximately $100 million for injectable hydrocortisone products. At the same time, Eton confirmed its commitment to ZENEO® Hydrocortisone as a disruptive solution for patients with adrenal insufficiency in its latest investor presentation dated 18 March 2025. The next stages of development and manufacturing, according to CROSSJECT’s plans, are expected from early 2026. Eton’s preliminary assessment of the market opportunity for ZENEO® Hydrocortisone would exceed $100 million. **** About CROSSJECT CROSSJECT SA (Euronext: ALCJ; www.CROSSJECT.com) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00031. For further information, please contact: Investor Relationinvestors@crossject.com APPENDICES – UNAUDITED FINANCIAL STATEMENTS INCOME STATEMENT (in K€) 31/12/2024 31/12/2023 VARIATION Revenue 0 145 -145 Other income BARDA 8 168 6 231 1 937 Subsidies 1 332 133 1 199 Stored production 30 591 -561 Capitalized production 2 783 3 594 -811 Reversals of provisions and transfers of expenses 944 2 631 -1 687 Operating income 13 256 13 326 -70 Purchases of raw materials and other supplies 2 004 1 625 379 Change in inventory (raw materials and other supplies) -381 -29 -352 Other purchases and external expenses 10 439 8 869 1 570 Taxes and duties 280 267 13 Personnel expenses 7 797 7 714 83 Depreciation, amortization 4 847 4 504 343 Other provisions 825 1 682 -857 Other expenses 408 494 -86 Operating expenses 26 219 25 126 1 093 Operating profit/loss -12 962 -11 800 -1 162 Financial income/expense -1 429 -497 -932 Exceptional income/expense -1 230 791 -2 021 Research Tax Credit 2 826 2 867 -41 Net profit/loss -12 795 -8 639 -4 156 BALANCE SHEET - ASSETS (in K€) 31/12/2024 31/12/2023 VARIATION FIXED ASSETS R&D 9 591 10 730 -1 139 Patent and Trademarks 0 0 0 Other intangible assets 5 0 5 Property, plant and equipment 2 126 2 750 -624 Assets under construction 2 924 2 942 -18 Financial assets 1 041 1 544 -503 TOTAL FIXED ASSETS 15 687 17 966 -2 279 CURRENT ASSETS Raw materials, other supplies 1 970 1 649 321 Work in process 1 448 1 485 -37 Other receivables 4 295 4 778 -483 Marketable securities 0 0 0 Available cash 7 036 2 304 4 732 Prepaid / deferred expenses 1 131 459 672 TOTAL CURRENT ASSETS 15 880 10 675 5 205 TOTAL ASSETS 31 567 28 641 2 926 BALANCE SHEET - LIABILITIES (in k€) 31/12/2024 31/12/2023 VARIATION CAPITAUX PROPRES Capital 4 554 3 676 878 Share premium 7 192 785 6 407 Regulated reserve 0 0 0 Retained earnings -2 596 -1 757 -839 Profit/loss for the year -12 795 -8 639 -4 156 Investment subsidies 972 665 307 TOTAL SHAREHOLDERS' EQUITY -2 673 -5 269 2 596 Conditional advances 5 391 7 060 -1 669 Provision for contingencies and charges 910 694 216 BORROWINGS AND DEBT Bonds 5 478 19 5 459 Loans 12 874 16 171 -3 297 Miscellaneous 2 717 2 732 -15 Debts - Trade payables 4 554 4 324 230 Total tax and social security liabilities 1 700 2 148 -448 Debts on fixed assets 0 82 -82 Deferred income 616 681 -65 TOTAL DEBT 27 939 26 156 1 783 TOTAL EQUITY AND LIABILITIES 31 567 28 641 2 926 CASH FLOW STATEMENT (IN K€) 31/12/2024 31/12/2023 Net profit / loss - 12 795 - 8 638 Depreciation, amortisation and provision 5 220 3 091 Net Book Value of Assets (NBV) 795 54 Other income and expenses calculated - 28 - 28 Share of subsidy transferred to result - 253 - Cashflow from operations - 7 061 - 5 521 Change in working capital requirements - 896 - 680 (1) Net cash generated by / (used in) operating activities - 7 957 - 6 201 Acquisition of fixed assets - 3 527 - 6 403 Disposal of fixed assets 100 3 767 (2) Net cash generated by / (used in) investing activities - 3 426 - 2 636 Capital increase 878 13 Exercice of warrants - 333 Additional Paid-in Capital (APIC) 14 207 Bonds 5 460 - Loans - 8 090 Repayment of borrowings / security deposit - 3 224 - 3 396 Subsidies 560 - Debts on fixed assets - 82 - 1 682 Repayment advances - 1 668 - (3) Net cash generated by / (used in) financing activities 16 130 3 358 Change in cash and cash equivalents (1)+(2)+(3) 4 746 - 5 480 Opening Cash position 2 291 7 770 Closing Cash position 7 038 2 291 Attachment PR FY 2024 Résultats financiers VF
The Leap from IBD to RIA: Unpacking a $700mm to $1.7B Growth Story - A Podcast for Financial Advisors - Diamond Consultants
Scott Pinkerton of FourThought Private Wealth offers a perspective on outgrowing the independent broker dealer model, transitioning to an independent RIA, and the extraordinary growth realized as a result of the change. Scott unpacks the difference between the models, shares why he opted to sell equity to Focus Financial, and more.
ICLR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages ICON plc Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action – ICLR - ForexTV
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the “Class Period”), of the important April 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the ICON class action, go to https://rosenlegal.com/submit-form/?case_id=34903 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting ICON’s client base; (2) ICON’s purported Functional Service Provision (“FSP”) and hybrid model offerings were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (4) ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (5) ICON’s two largest customers were diversifying their clinical research organization (“CRO”) providers away from ICON; (6) as a result of the above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (7) consequently, ICON was tracking materially below the 2024 revenue and earnings per share (“EPS”) guidance issued during the Class Period and such guidance lacked a reasonable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ICON class action, go to https://rosenlegal.com/submit-form/?case_id=34903 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
DEKUPLE: SOLID FULL-YEAR RESULTS FOR 2024 DESPITE THE INTENSITY OF STRATEGIC INVESTMENTS - ForexTV
SOLID FULL-YEAR RESULTS FOR 2024 DESPITE THE INTENSITY OF STRATEGIC INVESTMENTS_____ Net sales: €218m (+ 9.1%) Gross margin: €169m (+ 4.8%) EBITDA margin1: 13.9% of the gross marginNet income (Group share): €10.1m, representing 6.0% of the gross margin Proposed dividend: €0.76 per shareDevelopment in line with the Ambition 2025 plan Paris, 31 March 2025 (8:00am) - ADLPartner, the parent company of the DÉKUPLE Group, a European leader for data marketing and communication, is reporting its full-year earnings for 2024. Bertrand Laurioz, Dékuple Chairman and CEO: “2024 was a positive year for our Group, despite a difficult economic environment. The political and fiscal uncertainty led a number of businesses to be more cautious with their marketing investments. However, thanks to our leadership for Artificial Intelligence and our technological expertise, we maintained our strong competitive edge and confirmed our roadmap for growth. Our consolidated net sales are up + 9.1%, driven by the development of Digital Marketing, which now represents 65.6% of our total net sales, versus 36.5% in 2020, with + 15.8% growth in its gross margin year-on-year. Despite the increase in our investments, our net income (Group share) came to €10.1m, representing 6.0% of the gross margin, highlighting the relevance of our offers and the solidity of the Group's transformation. The Group continues to benefit from a robust balance sheet, with nearly €55m of shareholders’ equity and €58m of gross cash. The ramping up of investments for external growth is aligned with the Group's effective financial management, maintaining a positive net cash position and securing the resources needed for its sustainable development. The Group is looking ahead to 2025 with confidence, convinced that the digitalization and datafication of businesses will accelerate. Our teams are working to continue building on our profitable growth, driven by the strong development of digital marketing, which will continue to become increasingly important within the Group. Our strategy is based around sustained organic growth and targeted acquisitions, in France and across Europe. Alongside this, we are further strengthening our capacity for innovation by fully capitalizing on our technological expertise, particularly through the platformization of our services. We are also consolidating our societal and environmental commitments to supporting employability, training, responsible consumption, workplace wellness and promoting diversity, in line with our status as a European group with over 1,000 employees. While finalizing our Ambition 2025 plan to become a leading player in Europe for data marketing and communication, we are preparing the Horizon 2030 plan, which will structure our vision over the long term, with a view to strengthening our creative and technological leadership to help brands drive their transformation. Our Group benefits from a stable family shareholding structure, deep expertise, a network-based organization around multi-entrepreneurs, and a long-term vision. 2025 will be another year of success. Thank you to our employees, partners, clients and shareholders for their confidence, trust and loyalty”. KEY DEVELOPMENTS In 2024, DÉKUPLE made solid progress, thanks to the ramping up of its BtoB Digital Marketing activities, which now represent 65.6% of consolidated net sales, compared with 60.0% one year ago. Their gross margin, up + 15.8%, was supported by the development of consulting activities, the strengthening of marketing solutions and agencies, the international expansion and the acquisition of new expertise, including the full-year contribution by Le Nouveau Bélier (expert advertising strategy agency for Retail), as well as the integration of Ereferer (automated netlinking platform), GUD.Berlin (German communications agency) and Coup de Poing (expert BtoB client loyalty agency). On a like-for-like basis, our Digital Marketing activities recorded sustained organic growth, with their gross margin climbing + 7.4%, outpacing the market. This robust development helped offset the slowdown in BtoC activities, which, despite a challenging consumption environment, are continuing to roll out their investments with a view to acquiring recurring clients. In a press market that shows a marked decrease, the Magazine business limited its contraction to - 6.7%, while the Insurance business continued to perform well thanks to its innovative marketing approach. EARNINGS Consolidated net sales2 came to €217.8m, up + 9.1% compared with 2023, while the gross margin3 is up + 4.8% to €169.0m. Against a backdrop of sustained investments, restated EBITDA came to €23.6m, representing 13.9% of the full-year gross margin. Income from ordinary operations totaled €16.4m, representing 9.7% of the gross margin, compared with 10.8% in 2023. This change reflects contrasting trends: on the one hand, the decrease in EBIT for the Magazine business due to sustained commercial investments; on the other hand, the positive contribution by the Insurance business and the solid progress with results for Digital Marketing, making it possible to offset these effects. EBIT came to €14.1m, including -€2.3m of non-current expenses linked primarily to the partial depreciation of goodwill for the subsidiaries Groupe Grand Mercredi and Dékuple Ingénierie Marketing B2B (formerly AWE). Following a €4.6m tax expense, consolidated net income represents €10.3m, down - 19.8% from 2023, with a net margin rate of 6.1%, versus 8.0% in 2022. After deducting minority interests, net income (Group share) totaled €10.1m, compared with €12.4m in 2023. (€m)20242023Change 2024/2023 Net sales217.8199.7+9.1%Gross margin169.0161.2+4.8%Restated EBITDA23.624.9-5.6%% of gross margin13.9%15.5%-154 bpIncome from ordinary operations16.417.5-6.2%% of gross margin9.7%10.8%-115 bpEBIT14.117.5-19.4%% of gross margin8.3%10.8%-251 bpNet financial expenses / income0.80.4 Tax expense(4.6)(4.5) Share of net income from associates0.0(0.6) Consolidated net income10.312.9-19.8%% of gross margin6.1%8.0%-187 bpNet income (Group share)10.112.4-19.1%% of gross margin6.0%7.7%-176 bp BALANCE SHEET Consolidated shareholders’ equity at 31 December 2024 is up +€3.7m year-on-year to €54.8m. At 31 December 2024, the Group had €58.0m of cash, compared with €63.6m one year earlier, in line with the increase in investments for external growth, which reached €11.6m in 2024, compared with €4.6m in 2023. Financial debt totaled €55.0m, compared with €44.4m at 31 December 2023, including commitments to buy out minority interests in the Group’s subsidiaries. It also includes €21.3m of bank borrowings set up in 2022 at favorable interest rates to support the Group’s development. Cash net of financial liabilities4 at 31 December 2024 came to €3.0m, compared with €19.2m one year earlier. OUTLOOK In an uncertain economic environment, DÉKUPLE is continuing to move forward with its strategy to consolidate its European leadership for data marketing and communication. With its sound financial foundations, the Group is continuing to invest in its Magazine and Insurance activities to develop its portfolios generating recurrent revenues. Alongside this, the expansion of Digital Marketing is being ramped up, driven by organic growth and targeted acquisitions. Moving forward with its active approach to monitoring developments, DÉKUPLE is continuing to explore new opportunities for growth to expand its areas of expertise and further strengthen its support for brands in France and around the world. DIVIDEND Considering the results achieved in 2024 and the investments planned for 2025, ADLPartner’s Board of Directors will submit a proposal at the General Shareholders’ Meeting on 13 June 2025 for a dividend of €0.76 per share for FY 2024, to be paid out on 20 June 2025. ADDITIONAL INFORMATION The corporate and consolidated financial statements for 2024 were approved by the Board of Directors on 28 March 2025. The statutory auditors have completed the audit procedures on the corporate and consolidated accounts. The certification report will be issued once the necessary procedures have been finalized for publishing the full-year financial report. NEXT DATES 2024 annual financial report on 16 April 2025 before start of trading;2025 first-quarter net sales on 20 May 2025 before start of trading. About DÉKUPLE DÉKUPLE is a European leader for data marketing and communication. Its expert capabilities combining consulting, creativity, data and technology enable it to support brands with the transformation of their marketing to drive their business performance. The Group designs and implements client acquisition, loyalty and relationship management solutions for its partners and clients across all distribution channels. The Group works with more than 500 brands, from major groups to mid-market firms, in Europe and around the world. Founded in 1972, DÉKUPLE recorded net sales of €218m in 2024. Present in Europe, North America and China, the Group employs more than 1,000 people guided by its core values: a conquering spirit, respect and collaboration. DÉKUPLE is listed on the regulated market Euronext Paris – Compartment C. ISIN: FR0000062978 – DKUPL.www.dekuple.com ContactsDÉKUPLE Investor Relations & Financial Informationtel: +33 (0)1 41 58 72 03 - relations.investisseurs@dekuple.comACTUS FINANCE & COMMUNICATIONCyril Combe - tel: +33 (0)1 53 65 68 68 - dekuple@actus.fr 1 EBITDA (earnings before interest, tax, depreciation and amortization) is restated for the IFRS 2 impact of bonus share awards and the IFRS 16 impact relating to the restatement of lease charges.2 Net sales (determined in line with the French professional status for subscription sales) only include the amount of remuneration paid by magazine publishers; for subscription sales, net sales therefore correspond to a gross margin, deducting the cost of magazines sold from the amount of sales recorded. For acquisition and management commissions linked to sales of insurance policies, net sales comprise current and future commissions issued, acquired by the accounting reporting date, net of cancellations.3 For the digital marketing business, the gross margin represents the total amount of net sales (total invoices issued: fees, commissions and purchases charged back to clients) less the total amount of costs for external purchases made on behalf of clients. It is equal to net sales for the magazine and insurance business lines.4 Cash position on the balance sheet net of all financial liabilities. Attachment DEKUPLE_CP_resultats_annuels_2024_E
Notification of Share Transaction - ForexTV
ICG Enterprise Trust plc (the “Company”) 31 March 2025 Notification of Share Transaction The Company has received notification that on 28 March 2025, Oliver Gardey, Head of Private Equity Fund Investments at ICG, bought 1,721 ordinary shares in the Company at a price of 1270 pence per share. As a result of this transaction Oliver Gardey and his connected persons hold a total of 68,690 ordinary shares, being 0.108% of the ordinary share capital of the Company (excluding treasury shares). Analyst / Investor enquiries: Chris HuntShareholder Relations, ICG+44 (0) 20 3545 2020 Andrew LewisCompany Secretary, ICG+44 (0) 20 3545 1344 Media:Clare GlynnCorporate Communications, ICG+44 (0) 20 3545 1395
CBI Approves Capital Increase of €24 Million to Support 2025-2028 Strategic Plan
CBI S.c.p.a. Società Benefit, a leading developer of digital payment infrastructures, innovative services, and open finance ecosystems, announces the approval of share capital increase of approximately €24 million by its Shareholders during the Extraordinary General Meeting held earlier today. The Board of Directors has been granted the authority to execute the increase through both free and paid capital increases, to support the implementation of its 2025-2028 strategic plan.